Ticker
ACRS

Price
16.90
Stock movement up
+0.05 (0.30%)
Company name
Aclaris Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Diagnostics & Research
Markedsverdi
1.13B
Ent verdi
1.11B
Pris/omsetning
47.96
Pris/bok
5.13
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
62.97%
3 års avkastning
133.94%
5 års avkastning
-6.47%
10 års avkastning
-
Sist oppdatert: 2023-01-31

UTBYTTE

ACRS betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning47.96
Pris til bok5.13
EV i forhold til salg47.37

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall66.68M
EPS (TTM)-1.23
FCF per aksje (TTM)-0.99

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)23.50M
Bruttofortjeneste (TTM)11.90M
Driftsinntekter (TTM)-83.67M
Netto inntekt (TTM)-82.08M
EPS (TTM)-1.23
EPS (1 år fremover)-1.69

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)50.66%
Driftsmargin (TTM)-356.03%
Fortjenestemargin (TTM)-349.26%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter61.65M
Netto fordringer597.00K
Samlede omløpsmidler256.57M
Goodwill0.00
Immaterielle eiendeler6.99M
Eiendom, anlegg og utstyr0.00
Sum eiendeler267.63M
Leverandørgjeld7.67M
Kortsiktig/nåværende langsiktig gjeld766.00K
Sum kortsiktig gjeld19.79M
Sum gjeld47.79M
Aksjonærenes egenkapital219.84M
Netto varige driftsmidler212.85M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-65.53M
Kapitalutgifter (TTM)752.00K
Fri kontantstrøm (TTM)-66.28M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-37.34%
Avkastning på eiendeler-30.67%
Avkastning på investert kapital-37.21%
Kontantavkastning på investert kapital-30.04%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning16.88
Daglig høy17.50
Daglig lav16.73
Daglig volum452K
Tidenes høyeste32.99
1 år analytikerestimat32.50
Beta0.58
EPS (TTM)-1.23
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon22 Feb 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACRSS&P500
Nåværende prisfall fra toppnotering-48.77%-14.91%
Høyeste prisfall-97.73%-56.47%
Dato for høyeste fall18 Mar 20209 Mar 2009
Gj.snittlig fall fra topp-52.04%-11.49%
Gj.snittlig tid til ny topp77 days13 days
Maks tid til ny topp1459 days1805 days
SELSKAPSOPPLYSNINGER
ACRS (Aclaris Therapeutics Inc) company logo
Markedsverdi
1.13B
Markedsverdi kategori
Small-cap
Beskrivelse
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Ansatte
72
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Neal S. Walker
Land
USA
By
Malvern
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
6. januar 2023
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for ...
29. november 2022
This week's Lab Notes has updates from bioMerieux, Avisti Technologies, Aclaris Therapeutics and more.
26. november 2022
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walke...
22. november 2022
Aclaris Therapeutics is a biotech play that is focused on "leveraging core expertise in drug discovery and development and kinase inhibition to develop novel, small molecule therapies to help people ...
16. november 2022
WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
10. november 2022
Aclaris (ACRS) delivered earnings and revenue surprises of 23.08% and 1,083.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
8. november 2022
- Completed Enrollment in Phase 2a Trial of Zunsemetinib in Hidradenitis Suppurativa; Topline Data Expected in Mid-first Half of 2023 - Announced Patent License Agreement with Lilly for the Treatment ...
8. november 2022
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
26. oktober 2022
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
27. september 2022
Neste side